Drug Antitrust

MINNEAPOLIS – Boehringer Ingelheim conspired with Barr Pharmaceuticals et al. to delay introduction of a generic form of the stroke drug Aggrenox, costing consumers millions of dollars, a union health care fund claims in a federal antitrust class action.

Exit mobile version